



January - March 2011

**Sefton DAT** 

Quarter 4 2010/11

Martin Chandler and Steven Griffith

DRAFT REPORT The final version will be available on the IAD website

#### Acknowledgements:

The Authors would like to thank the NDTMS and DIP teams for their valuable support. We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts: Martin Chandler IAD Manager Centre for Public Health Faculty of Health & Applied Social Sciences Liverpool John Moores University 2nd Floor, Henry Cotton Campus, 15-21 Webster Street, Liverpool. L3 2ET

(0151) 231 4349

m.chandler@ljmu.ac.uk

Steven Griffith IAD Researcher

(0151) 231 4309 S.W.Griffith@ljmu.ac.uk

www.cph.org.uk/iad

Со	nte	nts

Introduction		P <u>age</u> 1
Arrest Referral		2
	Table 1: Individuals assessed, by Gender & Age Group	
	Table 2: Year to Date, by Gender and Age Group	
	Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Needle and Syrin	ge Programmes (NSPs)	4
Ag	ency	
	Table 4: Individuals by Gender	
	Table 5: Individuals by Gender: Steroid Users Omitted	
	Table 6: Individuals by Age Group	
	Table 7: Individuals by Age Group: Steroid Users Omitted	
	Table 8: Gender by Age Group of Individuals	
	Table 9: Gender by Age Group: Steroid Users Omitted	
	Table 10: Year to Date, by Gender & Age Group	
	Table 11: Year to Date, by Gender & Age Group: Steroid Users Omiti	ted
	Table 12: Main Drug of Use for New NSP Clients, by Gender	
	Table 13: Main Drug of Use for All NSP Clients, by Gender	
	Table 14: Year to Date; Main Drug of Use for All NSP Exchange Clien	ts, by
	Gender	
	Table 15: Main Drug of Use, for New NSP Clients, by Age Group	
Pha	armacy	10
	Table 16: Individuals by Gender	
	Table 17: Individuals by Site	

Table 18: Individuals by Age Group

Table 21: Individuals by Gender

- Table 19: Year to Date; by Gender & Age Group
- Table 20: Year to Date; by Gender & Age Group Steroid Users Omitted

#### Pharmacy 'Pick & Mix'

12

14

- Table 22: Individuals by Gender, Steroid Users Omitted
- Table 23: Main Drug of Use for All Clients, by Gender
- Table 24: Year to Date by Gender and Age Group
- Table 25: Year to Date by Gender and Age Group, Steroid Users Omitted

#### Combined

Table 26: Individuals in Agency and Pharmacy NSP, by Gender Table 27: Individuals in Agency and Pharmacy NSP, by Gender: Steroid Users omitted

- Table 28: Individuals in Agency and Pharmacy NSP, by Age Group Table 29: Individuals in Agency and Pharmacy NSP, by Age Group: Steroid Users omitted Table 30: Year to Date, by Gender & Age Group
- Table 31: Combined Pharmacy and Agency NSP Total Syringes Provided

#### **NSP Service Activity Summary**

16

18

21

22

Table 32: All NSP transactions by NSP Type Fig 1: NSP Service Activity; Transactions by NSP Type Table 33: NSP Transactions, Attributable Data Table 34: PNSP Transactions and Individuals by Site Table 35: All NSP Individuals by NSP Type Fig 2: NSP Service Activity; Individuals by NSP Type

#### National Drug Treatment Monitoring System (NDTMS)

Table 36: Individuals in Contact with Treatment Services, by Gender
Table 37: Year to Date, by Gender
Table 38: Individuals in Contact with Treatment Services, by Age Group
Table 39: Year to Date, by Age Group
Table 40: Ethnicity of Individuals in Contact with Treatment Services
Table 41: Individuals in contact with Treatment Services, by Main Drug of Use

#### **Combined Datasets**

Table 42: Total Problem Drug Users reported to the IAD, by Gender and Age Group Table 43: Year to Date Problem Drug Users, by Gender & Age Group

#### **Cross Matched Datasets**

Fig 3: Crossover between Agency NSP and NDTMS datasets

- Fig 4: Crossover between Pharmacy NSP and NDTMS datasets
- Fig 5: Crossover between YTD Agency NSP and NDTMS datasets
- Fig 6: Crossover between YTD Pharmacy NSP and NDTMS datasets

### Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle and syringe programmes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

#### Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

# **ARREST REFERRAL (AR)**

Quarter 4 (2010/11)

#### Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period. Data are based on initial contact in court or custody suites representing a sub section of the full DIP dataset, further information is available from the IAD on request.

Gender	n	%
Male	89	87.3
Female	13	12.7
Age Group		
Under 18	0	0.0
18-19	8	7.8
20-24	25	24.5
25-29	22	21.6
30-34	17	16.7
35-39	10	9.8
40-44	10	9.8
45+	10	9.8
Total	102	100

#### Table 1: Individuals assessed, by Gender & Age Group

#### Table 2: Year to Date, by Gender & Age Group

	Gender					
	Ma	ale	Fen	nale	Total in A	ge Group
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	27	7.8	3	5.1	30	7.4
20-24	88	25.3	6	10.2	94	23.1
25-29	70	20.1	10	16.9	80	19.7
30-34	52	14.9	12	20.3	64	15.7
35-39	43	12.4	7	11.9	50	12.3
40-44	37	10.6	8	13.6	45	11.1
45+	31	8.9	13	22.0	44	10.8
Total	348	100	59	100	407	100

Drug of Use	Daily	Weekly	Monthly
Amphetamines	0	1	0
Benzodiazepines	0	0	0
Cannabis	10	1	0
Crack	1	3	0
Cocaine	8	13	42
Ecstasy	0	0	0
Heroin	11	8	2
Methadone	0	0	0
Other	0	0	0

### Table 3: Reported Main Drug(s)\* of Use, by Frequency of Use

#### 2 individuals did not report a main drug of use

**NB:** The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily, Weekly or Monthly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

## **NEEDLE AND SYRINGE PROGRAMMES**

Quarter 4 (2010/11)

#### Introduction

NB: Data were not available from the Oriel Road site for this quarter. We are hoping to have updated figures for the next report.

#### **AGENCY NSP**

#### **Table 4: Individuals by Gender**

New Clients	n	%
Male	2	100
Female	0	0.0
Total	2	100
All Clients		
Male	39	92.9
Female	3	7.1
Total	42	100

### Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	0	0.0
Female	0	0.0
Total	0	0.0
All Clients		
Male	20	87.0
Female	3	13.0
Total	23	100

	New Clients		All Cl	ients
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	1	50.0	5	11.9
25-29	1	50.0	10	23.8
30-34	0	0.0	9	21.4
35-39	0	0.0	5	11.9
40-44	0	0.0	3	7.1
45+	0	0.0	10	23.8
Total	2	100	42	100

# Table 6: Individuals by Age Group

# Table 7: Individuals by Age Group: Steroid Users omitted

	New Clients		All Cl	ients
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	0	0.0	1	4.3
25-29	0	0.0	6	26.1
30-34	0	0.0	4	17.4
35-39	0	0.0	2	8.7
40-44	0	0.0	2	8.7
45+	0	0.0	8	34.8
Total	0	0	23	100

	Gender			
_	Ma	ale	Fen	nale
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	5	12.8	0	0.0
25-29	9	23.1	1	33.3
30-34	8	20.5	1	33.3
35-39	5	12.8	0	0.0
40-44	3	7.7	0	0.0
45+	9	23.1	1	33.3
Total	39	100	3	100

# Table 8: Gender by Age Group of Individuals

### Table 9: Gender by Age Group: Steroid Users omitted

	Gender			
	Ma	le	Fen	nale
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	1	5.0	0	0.0
25-29	5	25.0	1	33.3
30-34	3	15.0	1	33.3
35-39	2	10.0	0	0.0
40-44	2	10.0	0	0.0
45+	7	35.0	1	33.3
Total	20	100	3	100

	Gender					
	Ma	ale	Fen	nale	Total in A	ge Group
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	5	2.5	0	0.0	5	2.3
20-24	36	17.6	0	0.0	36	16.4
25-29	37	18.1	2	12.5	39	17.7
30-34	36	17.6	2	12.5	38	17.3
35-39	29	14.2	0	0.0	29	13.2
40-44	34	16.7	6	37.5	40	18.2
45+	27	13.2	6	37.5	33	15.0
Total	204	100	16	100	220	100

## Table 10: Year to Date, by Gender & Age Group

## Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

		Ger				
	Ma	ale	Fen	nale	Total in A	ge Group
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	0	0.0	0	0.0	0	0.0
20-24	7	8.2	0	0.0	7	7.0
25-29	10	11.8	2	13.3	12	12.0
30-34	18	21.2	2	13.3	20	20.0
35-39	14	16.5	0	0.0	14	14.0
40-44	18	21.2	6	40.0	24	24.0
45+	18	21.2	5	33.3	23	23.0
Total	85	100	15	100	100	100

	Gender				
	Ma	ale	Female		
Drug of Use	n	%	n	%	
Amphetamines	0	0.0	0	0.0	
Benzodiazepines	0	0.0	0	0.0	
Cocaine	0	0.0	0	0.0	
Crack	0	0.0	0	0.0	
Heroin	0	0.0	0	0.0	
Methadone	0	0.0	0	0.0	
Steroids	2	100	0	0.0	
Morphine	0	0.0	0	0.0	
Unknown	0	0.0	0	0.0	
Total	2	100	0	0.0	

## Table 12: Main Drug of Use for New Agency NSP Clients, by Gender

## Table 13: Main Drug of Use for All NSP Exchange Clients, by Gender

	Gender				
	Ma	ale	Female		
Drug of Use	n	%	n	%	
Amphetamines	0	0.0	0	0.0	
Benzodiazepines	0	0.0	0	0.0	
Cocaine	0	0.0	0	0.0	
Crack	0	0.0	0	0.0	
Heroin	9	23.1	2	66.6	
Methadone	2	5.1	0	0.0	
Morphine	0	0.0	0	0.0	
Steroids	19	48.7	0	0.0	
Unknown	9	23.1	1	33.3	
Total	39	100	3	100	

		Gender				
	M	ale	Female			
Drug of Use	n	%	n	%		
Amphetamines	1	< 1	0	0.0		
Benzodiazepines	0	0.0	0	0.0		
Cocaine	1	< 1	0	0.0		
Crack	0	0.0	0	0.0		
Heroin	38	18.6	10	62.5		
Methadone	5	2.5	1	6.3		
Morphine	0	0.0	0	0.0		
Steroids	108	52.9	0	0.0		
Various	0	0.0	1	6.3		
Unknown	51	25.0	4	25.0		
Total	204	100	16	100		

## Table 14: Year to Date; Main Drug of Use for All NSP Exchange Clients, by Gender

## Table 15: Main Drug of Use for Agency Syringe Exchange Clients, by Age Group

	•	heta- ine	Coc	aine	Hei	roin	Metha	adone	Ster	oids	Unkr	nown
Age Group	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	4	21.1	1	10.0
25-29	0	0.0	0	0.0	2	18.2	0	0.0	4	21.1	4	40.0
30-34	0	0.0	0	0.0	2	18.2	0	0.0	5	26.3	2	20.0
35-39	0	0.0	0	0.0	1	9.1	0	0.0	3	15.8	1	10.0
40-44	0	0.0	0	0.0	4	36.4	0	0.0	1	5.3	0	0.0
45+	0	0.0	0	0.0	4	36.4	2	100	2	10.5	2	20.0
Total	0	0.0	0	0.0	11	100	2	100	19	100	10	100

\* % Totals are by drug, not Age Group

## **PHARMACY NSPs**

## Table 16: Individuals by Gender

New Clients	n	%
Male	216	90.8
Female	22	9.2
Total	238	100
All Clients		
Male	446	90.7
Female	46	9.3
Total	492	100

## Table 17: Individuals by Gender Steroid Users Omitted\*

New Clients	n	%
Male	188	90.4
Female	20	9.6
Total	208	100
All Clients		
Male	399	90.1
Female	44	9.9
Total	443	100

\*Main drug of use is known for 'Pick and Mix' Clients Only

### Table 18: Individuals by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	2	< 1	2	< 1
18-19	5	2.1	6	1.2
20-24	34	14.3	48	9.8
25-29	43	18.1	67	13.6
30-34	36	15.1	71	14.4
35-39	37	15.5	86	17.5
40-44	44	18.5	112	22.8
45+	37	15.5	100	20.3
Total	238	100	492	100

		Ger				
	Ma	ale	Fen	nale	Total in A	ge Group
Age Group	n	%	n	%	n	%
Under 18	10	< 1	1	< 1	11	< 1
18-19	31	2.3	3	2.1	34	2.3
20-24	172	12.6	12	8.3	184	12.2
25-29	198	14.5	9	6.2	207	13.7
30-34	186	13.6	19	13.1	205	13.6
35-39	230	16.8	24	16.6	254	16.8
40-44	270	19.8	40	27.6	310	20.5
45+	268	19.6	37	25.5	305	20.2
Total	1,365	100	145	100	1,510	100

## Table 19: Year to Date; by Gender & Age Group

## Table 20: Year to Date; by Gender & Age Group, Steroid Users Omitted\*

		Ger				
	Ma	ale	Fen	nale	Total in A	ge Group
Age Group	n	%	n	%	n	%
Under 18	10	< 1	1	< 1	11	< 1
18-19	21	1.7	3	2.1	24	1.7
20-24	140	11.2	12	8.5	152	11.0
25-29	161	12.9	8	5.6	169	12.2
30-34	168	13.5	19	13.4	187	13.5
35-39	217	17.4	24	16.9	241	17.4
40-44	264	21.2	39	27.5	303	21.8
45+	264	21.2	36	25.4	300	21.6
Total	1,245	100	142	100	1,387	100

\*Main drug of use is known for 'Pick and Mix' Clients Only

## **PHARMACY NSP - SEFTON PICK AND MIX**

Data presented here are included within the pharmacy NSP data presented on pages 10 and 11. The following data provide information of service activity in 'pick and mix' pharmacy NSP services in Sefton only.

New Clients	n	%
Male	56	90.3
Female	6	9.7
Total	62	100
All Clients		
Male	113	91.9
Female	10	8.1
Total	123	100

#### Table 21: Individuals by Gender

#### Table 22: Individuals by Gender, Steroid Users Omitted

New Clients	n	%
Male	28	87.5
Female	4	12.5
Total	32	100
All Clients		
Male	66	89.2
Female	8	10.8
Total	74	100

#### Table 23: Main Drug of Use for All Clients by Gender

	Gender				
	Ma	ale	Fen	nale	
Drug of Use	n	%	n	%	
Cocaine	0	0.0	0	0.0	
Crack	3	2.7	0	0.0	
Heroin	41	36.3	3	30.0	
Methadone	5	4.4	0	0.0	
Steroids	47	41.6	2	20.0	
Unknown	17	15.0	5	50.0	
Total	113	100	10	100	

	Gender					
	Male		Fen	nale	Total in A	ge Group
Age Group	n	%	n	%	n	%
Under 18	3	< 1	0	0.0	3	< 1
18-19	18	5.3	1	3.0	19	5.1
20-24	58	17.2	2	6.1	60	16.2
25-29	60	17.8	1	3.0	61	16.4
30-34	39	11.5	5	15.2	44	11.9
35-39	57	16.9	7	21.2	64	17.3
40-44	70	20.7	5	15.2	75	20.2
45+	33	9.8	12	36.4	45	12.1
Total	338	100	33	100	371	100

## Table 24: Year to Date by Gender and Age Group

## Table 25: Year to Date by Gender and Age Group, Steroid Users Omitted

	Gender					
	Ma	ale	Fen	nale	Total in A	ge Group
Age Group	n	%	n	%	n	%
Under 18	3	1.6	0	0.0	3	1.4
18-19	3	1.6	1	3.4	4	1.9
20-24	14	7.7	2	6.9	16	7.6
25-29	18	9.9	0	0.0	18	8.5
30-34	18	9.9	5	17.2	23	10.9
35-39	38	20.9	7	24.1	45	21.3
40-44	60	33.0	3	10.3	63	29.9
45+	28	15.4	11	37.9	39	18.5
Total	182	100	29	100	211	100

# **COMBINED PHARMACY AND AGENCY NSP**

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

New Clients	n	%
Male	216	90.8
Female	22	9.2
Total	238	100
All Clients		
Male	446	90.7
Female	46	9.3
Total	492	100

Table 26: Individuals in Agency and Pharmacy NSP, by Gender

Table 27: Individuals in Agency and Pharmacy NSP, by Gender: Steroid Users Omitted\*

New Clients	n	%
Male	188	90.4
Female	20	9.6
Total	208	100
All Clients		
Male	399	90.1
Female	44	9.9
Total	443	100

\*Only known steroid users, based on Agency NSP data and some Pharmacy NSP, have been omitted.

 Table 28: Individuals in Agency and Pharmacy NSP , by Age Group

	New Clients All Clients			ients	
Age Group	n	%	n	%	
Under 18	2	0.8	2	0.4	
18-19	5	2.1	6	1.2	
20-24	34	14.3	48	9.8	
25-29	43	18.1	67	13.6	
30-34	36	15.1	71	14.4	
35-39	37	15.5	86	17.5	
40-44	44	18.5	112	22.8	
45+	37	15.5	100	20.3	
Total	238	100	492	100	

	New Clients		All Cl	ients
Age Group	n	%	n	%
Under 18	2	1.0	2	0.5
18-19	4	1.9	4	0.9
20-24	26	12.5	37	8.4
25-29	32	15.4	49	11.1
30-34	32	15.4	64	14.4
35-39	32	15.4	79	17.8
40-44	43	20.7	110	24.8
45+	37	17.8	98	22.1
Total	208	100	443	100

#### Table 29: Individuals in Agency and Pharmacy NSP, by Age Group: Steroid Users Omitted

#### Table 30: Year to Date, by Gender & Age Group

	Gender					
	Ma	ale	Fen	nale	Total in A	ge Group
Age Group	n	%	n	%	n	%
Under 18	10	0.6	1	0.6	11	0.6
18-19	41	2.6	3	1.9	44	2.6
20-24	216	13.8	12	7.6	228	13.2
25-29	237	15.2	11	7.0	248	14.4
30-34	216	13.8	20	12.7	236	13.7
35-39	258	16.5	24	15.2	282	16.4
40-44	305	19.5	46	29.1	351	20.4
45+	280	17.9	41	25.9	321	18.7
Total	1,563	100	158	100	1,721	100

#### Table 31: Combined Pharmacy and Agency NSP Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	1,832	17,189	19,021	96,912

**NB:** We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

# NSP SERVICE ACTIVITY SUMMARY


Data presented here illustrate service activity across all NSP types including number of transactions, proportion of data that are attributable and a split of activity by NSP type. Individuals by NSP type are also summarised for comparative purposes.

All Transactions	n	%
Bootle Oriel Road	0	0.0
Pick and Mix	381	27.5
Southport CDT	71	5.1
Pharmacy NSPs*	932	67.4
Total	1,384	100

Table 32: All NSP transactions by NSP Type

\*Excluding Pick and Mix Data

#### Fig 1: NSP Service Activity; Transactions by NSP Type



#### Table 33: NSP Transactions, Attributable Data

All Transactions	n	%†
Bootle Oriel Road	0	0.0
Pick and Mix	341	26.8
Southport CDT	59	4.7
Pharmacy NSPs*	871	68.5
Total	1,271	100

<sup>†</sup>Represents proportion of transactions that were attributable during the current quarter.

\*Excluding Pick and Mix Data


	Transactions		Indivi	duals
PNSP Site	n	%	n	%
Alliance Southport	5	< 1	2	< 1
Boots Seaforth	263	28.2	181	48.0
Boots Waterloo	16	1.7	6	1.6
Cohens Netherton	112	12.0	36	9.5
Davey's Randall Drive	332	35.6	77	20.4
Hirshman's Ainsdale	49	5.3	0	0.0
Rowlands Birkdale	22	2.4	8	2.1
Superdrug Southport	133	14.3	67	17.8
Total	932	100	377	100

## Table 34: PNSP Transactions and Individuals by Site

## Table 35: All NSP Individuals by NSP Type

All Transactions	n	%
Bootle Oriel Road	0	0.0
Pick and Mix	123	22.7
Southport CDT	42	7.7
Pharmacy NSPs*	377	69.6
Total	542	100

## Fig 2: NSP Service Activity; Individuals by NSP Type



# National Drug Treatment Monitoring System (NDTMS) Quarter 4 (2010/11)

#### Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

#### **New Clients**

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or are in contact with treatment services, before this period.

New Clients	n	%
Male	240	79.5
Female	62	20.5
Total	302	100
All Clients		
Male	1,310	74.5
Female	449	25.2
Total	1,759	100

Table 36: Individuals in Contact with Treatment Services, by Gender

#### Table 37: Year to Date, by Gender

New Clients	n	%
Male	686	79.1
Female	181	20.9
Total	867	100
All Clients		
Male	1,389	74.8
Female	468	25.2
Total	1,857	100

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	31	10.3	162	9.2
18-19	10	3.3	59	3.4
20-24	35	11.6	170	9.7
25-29	43	14.2	225	12.8
30-34	32	10.6	305	17.3
35-39	48	15.9	378 21.5	
40-44	56	18.5	266 15.1	
45+	47	15.6	194	11.0
Total	302	100	1,759 100	

## Table 38: Individuals in Contact with Treatment Services, by Age Group

Table 39: Year to Date, Individuals in Contact with Treatment Services, by Age Group

	New Clients		All Clients	
Age Group	n	n %		%
Under 18	113	13.0	164	8.8
18-19	39	4.5	61	3.3
20-24	102	11.8	175	9.4
25-29	123	14.2	233	12.5
30-34	121	14.0	311	16.7
35-39	141	16.3	396 21.3	
40-44	131	15.1	302 16.3	
45+	97	11.2	215	11.6
Total	867	100	1,857	100

	New Clients		All Cl	ients
Ethnicity	n %		n	%
White British	289	95.7	1,701	96.7
White Irish	2	< 1	6	< 1
Other White	5	1.7	25	1.4
White & Black Caribbean	1	< 1	4	< 1
Other Black	0	0.0	4	< 1
White & Asian	0	0.0	1	< 1
Other Asian	0	0.0	2	< 1
Other Mixed	2	< 1	6	< 1
Caribbean	0	0.0	0	0.0
Chinese	1	< 1	3	< 1
Other	2	< 1	5	< 1
Unknown	0	0.0	2	< 1
Total	302	100	1,759	100

### Table 40: Ethnicity of Individuals in Contact with Treatment Services

# Table 41: Individuals in Contact with Treatment Services, by Main Drug of Use

	New C	Clients	All Clients		
Drug of Use	n %		n	%	
Heroin	136	45.0	1,062	60.4	
Methadone	7	2.3	63	3.6	
Other Opiates	12	4.0	33	1.9	
Benzodiazepines	1	< 1	5	< 1	
Amphetamines	2	< 1	10	< 1	
Cocaine	81	26.8	293	16.7	
Crack	15	5.0	57	3.2	
Hallucinogens	0	0.0	2	< 1	
Ecstasy	0	0.0	1	< 1	
Cannabis	48	15.9	222	12.6	
Antidepressants	0	0.0	0	0.0	
Prescription Drugs	0	0.0	3	< 1	
Mephedrone	0	0.0	2	< 1	
Other/Unknown	0	0.0	6	< 1	
Total	302	100	1,759	100	

### **COMBINED DATASETS**

#### Quarter 4 (2010/11)

#### Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, NSPs (Agency and Pharmacy) and NDTMS. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Gender	n %	
Male	1,686	77.8
Female	481	22.2
Age Group		
Under 18	164	7.6
18-19	64	3.0
20-24	212	9.8
25-29	288	13.3
30-34	355	16.4
35-39	440	20.3
40-44	361	16.7
45+	283	13.1
Total	2,167	100

#### Table 42: Total Problem Drug Users reported to the IAD, by Gender and Age Group

#### Table 43: Year to Date, by Gender and Age Group

	Gender					
	Ma	Male Female			Total in Age Group	
Age Group	n	%	n	%	n	%
Under 18	138	4.7	35	5.7	173	4.9
18-19	106	3.6	13	2.1	119	3.4
20-24	391	13.4	42	6.8	433	12.3
25-29	414	14.2	74	12.0	488	13.8
30-34	415	14.3	107	17.4	522	14.8
35-39	504	17.3	133	21.6	637	18.1
40-44	507	17.4	117	19.0	624	17.7
45+	436	15.0	95	15.4	531	15.1
Total	2,911	100	616	100	3,527	100


# **CROSS-MATCHED DATASETS**

#### Quarter 4 (2010/11)

Data are shown for the crossover between each type of Needle and Syringe Programme and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.


For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of needle and syringe programme site.



### Fig 3: Current Quarter Crossover between Agency NSP and NDTMS datasets

#### Fig 4: Current Quarter Crossover between Pharmacy NSP and NDTMS Datasets








Fig 6: Year to Date Crossover between Pharmacy NSP and NDTMS datasets

